Oh Tak Kyu, Jeon Jae Hyun, Lee Jong Mog, Kim Moon Soo, Kim Jee Hee, Cho Hyeyeon, Kim Seong-Eun, Eom Woosik
Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Republic of Korea.
Department of Thoracic Surgery, National Cancer Center, 323, Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, Republic of Korea.
PLoS One. 2017 Jul 21;12(7):e0181672. doi: 10.1371/journal.pone.0181672. eCollection 2017.
Opioids are commonly used for postoperative pain control in cancer patients. In addition to pain control, an association between opioid use and long-term oncologic outcomes, such as recurrence or overall survival, has been postulated. The aim of this study was to determine whether postoperative opioid use in patients with non-small cell lung cancer is associated with long-term oncologic outcomes, including recurrence and death. Data obtained from 1009 medical records of patients who underwent curative resection at the National Cancer Center, Korea between January 2006 and December 2010 were retrospectively analyzed. Seven-day opioid use was divided into four quartiles to analyze probability of recurrence and death. Multivariate regression analyses of recurrence and death was conducted, including the calculation of odds ratios. A total of 871 patients were analyzed. When opioid dosage was examined by quartiles, the probability of death and recurrence increased gradually with increasing opioid use. However, in the multivariate regression analysis, the amount of opioid usage did not affect the risk of recurrence or death of lung cancer (P = 0.520 for recurrence; P = 0.659 for death). Opioid use was correlated with outcome when stratified by lung cancer stage (P = 0.004 for recurrence; P = 0.049 for death); however, the odds ratios only slightly increased (1.001 for stage IA-IIIA) for both outcomes. In non-small cell lung cancer patients, the amount of opioid usage does not affect the risk of recurrence and death of lung cancer. There was an association with stage (IA-IIIA), but the effect was negligible. A well-designed prospective study is needed.
阿片类药物常用于癌症患者的术后疼痛控制。除疼痛控制外,还推测阿片类药物的使用与长期肿瘤学结局(如复发或总生存期)之间存在关联。本研究的目的是确定非小细胞肺癌患者术后使用阿片类药物是否与包括复发和死亡在内的长期肿瘤学结局相关。对2006年1月至2010年12月在韩国国立癌症中心接受根治性切除术的1009例患者的病历数据进行回顾性分析。将7天阿片类药物使用量分为四个四分位数,以分析复发和死亡概率。对复发和死亡进行多变量回归分析,包括计算比值比。共分析了871例患者。按四分位数检查阿片类药物剂量时,死亡和复发概率随阿片类药物使用量增加而逐渐升高。然而,在多变量回归分析中,阿片类药物使用量并未影响肺癌复发或死亡风险(复发P = 0.520;死亡P = 0.659)。按肺癌分期分层时,阿片类药物使用与结局相关(复发P = 0.004;死亡P = 0.049);然而,两种结局的比值比仅略有升高(IA-IIIA期为1.001)。在非小细胞肺癌患者中,阿片类药物使用量不影响肺癌复发和死亡风险。与分期(IA-IIIA)存在关联,但影响可忽略不计。需要进行精心设计的前瞻性研究。